SS Innovations International earnings release, August 13, 2026

SS Innovations International, Inc. (SSII) · Form 8-K, Item 2.02 · Filed · SEC filing

SS Innovations Reports Second Quarter 2026 Financial

Results

Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales

FORT LAUDERDALE, FLA – August 13, 2026 – SS Innovations International, Inc.

(the “Company” or “SS

Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2026. The

Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission on August 13, 2026.

Second Quarter 2026 Overview

First Half 2026 Overview

As of June 30, 2026

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and

Chief Executive Officer of SS Innovations, commented, “SS Innovations delivered record quarterly revenue of $13.9 million in the second quarter of 2026, up 39% year over year, reflecting strong adoption of our advanced SSi Mantra surgical robotic system by leading hospitals and surgeons in India and abroad. We continue to expand awareness of the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Recently the SSi Mantra has been showcased in several high-profile international long-distance telesurgeries as well as at this year’s Global Multi-Specialty Robotic Surgery

Conference in New Delhi, which we hosted, and the 2026 Society of Robotic Surgery Annual Meeting in Florida. We appreciate the widespread positive reception of the SSi Mantra at these events and were excited to win the ‘Outstanding Company’ category at the 2026

Surgical Robotics Industry Awards in June.”

Dr. Srivastava continued, “We remain enthusiastic about our ability to lead our foundational market of India, which is immense and growing, while expanding our global footprint in underserved countries and aiming for entry into the United States and European Union. We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain by the end of 2026. Our SSI

Mantra has been engineered for precision, built to perform, and created to democratize access to advanced surgical robotic care—all underpinning our confidence in the future.”

Select Business Highlights in Second Quarter

2026²

Subsequent Event

Revenue Breakdown and Summary of Installations

/ Surgeries

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.³

About the SSi Mantra

The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

Forward Looking Statements

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,”

“intend,” “may,” “plan,” “project,” “should,” “could,” “seek,”

Financial statements

Income Statement

Revenue Breakdown and Summary of Installations / Surgeries

Q2 2025Q2 2026VariancePercentage
System sales8,781,03812,361,9863,580,94840.8%
Instrument sales1,007,8301,142,525134,69513.4%
Warranty sales193,359419,002225,643116.7%
Lease income18,07816,196-1,882-10.4%
Total revenue10,000,30513,939,7093,939,40439.4%
SSi Mantra installations2330730.4%
Cumulative installed base1105224119113.3%
SSi Mantra surgeries1,0422,5281,486142.6%
Cumulative surgeries14,65712,2727,615163.5%

Income Statement

Revenue Breakdown and Summary of Installations / Surgeries

H1 2025H1 2026VariancePercentage
System sales13,283,52021,937,3568,653,83665.1%
Instrument sales1,485,0382,293,753808,71554.5%
Warranty sales315,863776,688460,825145.9%
Lease income36,49433,278-3,216-8.8%
Total revenue15,120,91525,041,0759,920,16065.6%
SSi Mantra installations38561847.4%
SSi Mantra surgeries1,8614,3872,526135.7%

Income Statement

For The Three months ended — (Unaudited)

For The Three months ended – June 30, 2026For The Three months ended – June 30, 2025
REVENUESSystem sales12,361,9868,781,038
REVENUESInstrument sales1,142,5251,007,830
REVENUESWarranty sales419,002193,359
REVENUESLease income16,19618,078
REVENUESTotal revenue13,939,70910,000,305
REVENUESCost of revenue-6,838,759-4,085,247
REVENUESGROSS PROFIT7,100,9505,915,058
OPERATING EXPENSES:Research & development expense2,395,694498,600
OPERATING EXPENSES:Stock-based compensation expense2,178,1561,630,295
OPERATING EXPENSES:Depreciation and amortization expense346,364260,361
OPERATING EXPENSES:Selling, general and administrative expense4,452,0903,428,788
OPERATING EXPENSES:TOTAL OPERATING EXPENSES9,372,3045,818,044
OPERATING EXPENSES:(Loss) / Profit from operations-2,271,35497,014
OTHER INCOME/ (EXPENSE):Interest Expense-344,761-216,800
OTHER INCOME/ (EXPENSE):Interest and other income, net460,041216,824
OTHER INCOME/ (EXPENSE):TOTAL OTHER INCOME, NET115,28024
OTHER INCOME/ (EXPENSE):(LOSS) / PROFIT BEFORE INCOME TAXES-2,156,07497,038
OTHER INCOME/ (EXPENSE):Income tax expense505,276353,729
OTHER INCOME/ (EXPENSE):NET LOSS-2,661,350-256,691
OTHER INCOME/ (EXPENSE):Net loss per share - basic and diluted-0.010
OTHER INCOME/ (EXPENSE):Weighted average- basic shares200,136,068193,571,635
OTHER INCOME/ (EXPENSE):Weighted average- diluted shares209,422,550202,835,698
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSSNET LOSS-2,661,350-256,691
OTHER COMPREHENSIVE LOSSForeign currency translation loss-404,867-66,014
OTHER COMPREHENSIVE LOSSRetirement Benefit-25,651-35,660
RECLASSIFICATION ADJUSTMENTS:Retirement Benefit (1)3,033
RECLASSIFICATION ADJUSTMENTS:Income tax effects relating to retirement benefit (1)6,4565,772
RECLASSIFICATION ADJUSTMENTS:TOTAL OTHER COMPREHENSIVE LOSS-421,029-95,902
RECLASSIFICATION ADJUSTMENTS:TOTAL COMPREHENSIVE LOSS-3,082,379-352,593

Income Statement

For The Six months ended — (Unaudited)

For The Six months ended – June 30, 2026For The Six months ended – June 30, 2025
REVENUESSystem sales21,937,35613,283,520
REVENUESInstrument sales2,293,7531,485,038
REVENUESWarranty sales776,688315,863
REVENUESLease income33,27836,494
REVENUESTotal revenue25,041,07515,120,915
REVENUESCost of revenue-12,612,904-8,118,649
REVENUESGROSS PROFIT12,428,1717,002,266
OPERATING EXPENSES:Research & development expense3,391,1341,508,695
OPERATING EXPENSES:Stock-based compensation expense5,322,4714,009,507
OPERATING EXPENSES:Depreciation and amortization expense670,111469,243
OPERATING EXPENSES:Selling, general and administrative expense8,941,3876,638,587
OPERATING EXPENSES:TOTAL OPERATING EXPENSES18,325,10312,626,032
OPERATING EXPENSES:Loss from operations-5,896,932-5,623,766
OTHER INCOME/ (EXPENSE):Interest Expense-628,812-596,705
OTHER INCOME/ (EXPENSE):Interest and other income, net938,451636,156
OTHER INCOME/ (EXPENSE):TOTAL OTHER INCOME, NET309,63939,451
OTHER INCOME/ (EXPENSE):LOSS BEFORE INCOME TAXES-5,587,293-5,584,315
OTHER INCOME/ (EXPENSE):Income tax expense656,628353,729
OTHER INCOME/ (EXPENSE):NET LOSS-6,243,921-5,938,044
OTHER INCOME/ (EXPENSE):Net loss per share - basic and diluted-0.03-0.03
OTHER INCOME/ (EXPENSE):Weighted average- basic shares198,083,415186,244,872
OTHER INCOME/ (EXPENSE):Weighted average- diluted shares207,369,897195,502,268
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSSNET LOSS-6,243,921-5,938,044
OTHER COMPREHENSIVE LOSSForeign currency translation loss-1,961,978-59,138
OTHER COMPREHENSIVE LOSSRetirement Benefit-20,870-19,822
RECLASSIFICATION ADJUSTMENTS:Retirement Benefit (1)6,089
RECLASSIFICATION ADJUSTMENTS:Income tax effects relating to retirement benefit (1)5,2535,772
RECLASSIFICATION ADJUSTMENTS:TOTAL OTHER COMPREHENSIVE LOSS-1,971,506-73,188
RECLASSIFICATION ADJUSTMENTS:TOTAL COMPREHENSIVE LOSS-8,215,427-6,011,232

Balance Sheet

CONDENSED CONSOLIDATED BALANCE SHEETS

As of – June 30, 2026 – (Unaudited)As of – December 31, 2025
Current Assets:Cash and cash equivalents13,647,4303,206,406
Current Assets:Restricted cash8,648,4615,937,650
Current Assets:Accounts receivable, net16,986,08912,398,542
Current Assets:Inventory18,481,60317,064,002

Cash Flow

For the six months ended — (Unaudited)

For the six months ended – June 30, 2026For the six months ended – June 30, 2025
Cash flows from operating activities:Net loss-6,243,921-5,938,044
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization670,111469,243
Adjustments to reconcile net loss to net cash used in operating activities:Operating lease expense471,459423,593
Adjustments to reconcile net loss to net cash used in operating activities:Interest expense84,938179,455
Adjustments to reconcile net loss to net cash used in operating activities:Interest and other income, net-814,218-338,191
Adjustments to reconcile net loss to net cash used in operating activities:Deferred income tax benefit-336,457-365,641
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense5,368,3304,009,507
Adjustments to reconcile net loss to net cash used in operating activities:Provision for / (reversal of) credit loss reserve, net297,882-228,846
Adjustments to reconcile net loss to net cash used in operating activities:Provision for slow moving inventory-6,225
Changes in operating assets and liabilities:Accounts receivable, net-4,286,490-2,337,679
Changes in operating assets and liabilities:Inventory, net-1,411,376-10,221,214
Changes in operating assets and liabilities:Deferred revenue2,205,5011,739,652
Changes in operating assets and liabilities:Prepaids and other assets-3,955,550-2,572,481
Changes in operating assets and liabilities:Accounts payable127,7283,782,409
Changes in operating assets and liabilities:Income taxes payable, net933,184620,586
Changes in operating assets and liabilities:Accrued expenses & other liabilities782,7871,629,136
Changes in operating assets and liabilities:Operating lease payment-434,132-407,188
Changes in operating assets and liabilities:Net cash used in operating activities-6,546,449-9,555,703
Cash flows from investing activities:Purchase of property, plant and equipment-215,060-1,189,452
Cash flows from investing activities:Net cash used in investing activities-215,060-1,189,452
Cash flows from financing activities:Proceeds from bank overdraft facility (net)3,192,012-1,014,593
Cash flows from financing activities:Proceeds from private investment in public equity, net of transaction costs18,446,498
Cash flows from financing activities:Proceeds from issuance of convertible notes to principal shareholder28,000,000
Cash flows from financing activities:Repayment of convertible notes to principal shareholder, including interest-4,212,637
Cash flows from financing activities:Repayment of convertible notes to other investors, including interest-1,068,849
Cash flows from financing activities:Net cash provided by financing activities21,638,51021,703,921
Cash flows from financing activities:Net change in cash14,877,00110,958,766
Cash flows from financing activities:Effect of exchange rate on cash-1,808,99823,377
Cash flows from financing activities:Cash and cash equivalents at the beginning of the period9,603,0206,623,535
Cash flows from financing activities:Cash and cash equivalents at end of the period22,671,02317,605,678
Full release

“designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:

The Equity Group

Kalle Ahl, CFA

T: (303) 953-9878 kalle.ahl@theequitygroup.com

Devin Sullivan, Managing Director

T: (212) 836-9608 devin.sullivan@theequitygroup.com

Media Contact:... (truncatedLLC

Kate Barrette

T: (212) 223-0561 kbarrette@rooneypartners.com⁴

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.